Navigation Links
Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program

CAMBRIDGE, Mass., April 26, 2012 /PRNewswire/ -- Galenea Corp., a leader in the rapidly emerging field of synaptic transmission, today announced that The Stanley Medical Research Institute (SMRI) will provide $6 million in an equity investment to support the development of Galenea's innovative pro-cognitive discovery program and the selection of a clinical candidate for the treatment of schizophrenia and other psychiatric disorders.  The funding is expected to advance the therapeutic candidate through the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.  The program includes a proteomics collaboration with the Broad Institute as part of a broader effort being undertaken by The Stanley Center for Psychiatric Research.  This center was created by a grant from SMRI. Dr. Edward Scolnick, who founded the Broad Institute's Psychiatric Disease Program, currently serves as the Center's Chief Scientific Officer.  The proteomics collaboration will be led at the Broad Institute by Dr. Steven Carr, director of the Proteomics Platform.

Mark Benjamin, DSc, President and CEO of Galenea, said "We are delighted about this funding from SMRI and the collaboration with the Broad Institute.  A core objective of SMRI is the development of treatments for schizophrenia, and we therefore view their investment in Galenea as an endorsement of our cutting-edge approach to identifying novel therapeutics. We truly appreciate the support."

Galenea's proprietary technology, the MANTRA™ (Multiwell, Automated NeuroTRansmission Assay) system, enables direct high throughput screening of synaptic function in cultured primary neurons from mice and rats, and in neurons derived from human induced pluripotent stem cells.  Changes in synaptic function are now believed to play a central role in many psychiatric, neurological and neurodegenerative diseases. Galenea is using the MANTRA™ system to characterize synaptic dysfunctions in disease models and to identify signatures of therapeutic compound classes.  A lead series of compounds discovered using the MANTRA™ system has demonstrated efficacy in several animal models of memory and schizophrenia.  This program, which also receives significant support from NIMH, should deliver an IND candidate in 2015.

"We expect the collaboration with the Broad Institute to lead to significant advances in the application of proteomics to neuroscience drug discovery," said David Gerber, PhD, Vice President of CNS Research at Galenea.  "We have made significant progress in identifying modulators of synaptic transmission since we developed and validated our MANTRA™ screening technology, and the funding will enable Galenea to progress a novel therapeutic candidate for schizophrenia to the clinic."

About Galenea  
Galenea is a leader in the rapidly emerging field of synaptic transmission (ST), the process by which neurons communicate with each other.  Dysfunctions in ST are now widely believed to play a central role in many psychiatric, neurological and neurodegenerative diseases, and modulators of ST therefore have the potential to yield breakthrough treatments. Galenea has developed an innovative ST drug discovery platform that integrates three components: MANTRA™, a high throughput, proprietary screening technology to identify a new generation of small molecule modulators of synaptic transmission; in vivo models using integrated EEG measures of animal behavior to more reliably determine CNS drug efficacy; and human EEG biomarkers, developed in tandem with and informed by our animal EEG data to greatly enhance CNS drug development.   The company is advancing a novel pro-cognitive program derived from the platform and the approach can be extended to address multiple CNS disorders.  Based in Cambridge, MA, Galenea has assembled a compelling scientific team, balancing academic aptitude with industry experience and entrepreneurship.  For more information about Galenea, please visit the company's website at

About SMRI
The Stanley Medical Research Institute (SMRI) is a nonprofit organization that supports research on the causes and treatment of schizophrenia and bipolar disorder (manic-depressive illness), both through work carried out in its own laboratories and through support of researchers worldwide who are working on these diseases. SMRI has provided over $400 million in funding since 2001.  Schizophrenia and bipolar disorder are major psychiatric disorders in the United States, affecting more than 4 million people.

About the Broad Institute of Harvard and MIT
The Eli and Edythe L. Broad Institute of Harvard and MIT was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.

Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to

SOURCE Galenea Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration
2. Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntingtons Disease
3. Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... ProSidebar: Fashion is a set of 30 kinetic edge ... video editors can easily add an informative sidebar to any FCPX production. Create ... featuring self-animating drop zones, lines, bars, and text with the ease of FCPX's drag ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood ... issues that are presently affecting Americans. Dedicated to providing the world with a wide ... subjects consumers focus on, one episode at a time. , In the latest ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/26/2015)... ... 26, 2015 , ... Patients at Serenity Point Recovery, a ... on Thanksgiving Day to share the things that they are most grateful for ... YouTube channel, patients displayed what they wrote on index cards, describing the things ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):